APA (7th ed.) Citation

Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Müller, M. C., Pletsch, N., . . . Saußele, S. (2011). Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia. Journal of clinical oncology, 29(12), 1634-1642. https://doi.org/10.1200/JCO.2010.32.0598

Chicago Style (17th ed.) Citation

Hehlmann, Rüdiger, et al. "Tolerability-Adapted Imatinib 800 Mg/d Versus 400 Mg/d Versus 400 Mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia." Journal of Clinical Oncology 29, no. 12 (2011): 1634-1642. https://doi.org/10.1200/JCO.2010.32.0598.

MLA (9th ed.) Citation

Hehlmann, Rüdiger, et al. "Tolerability-Adapted Imatinib 800 Mg/d Versus 400 Mg/d Versus 400 Mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia." Journal of Clinical Oncology, vol. 29, no. 12, 2011, pp. 1634-1642, https://doi.org/10.1200/JCO.2010.32.0598.